Changzheng Du

Associate Professor School of Medicine

Prof. Du has been working as a senior doctor in surgical treatment of digestive malignant tumor for decades, with abundant clinical experience. He performed the first clinical trial of non-surgery treatment for rectal cancer in China, which was displayed at the 2017 ASCO meeting. Prof. Du uses basic research to solve clinical problems, focusing on translating lab work into clinic use. His research fields including cancer molecular biology, signal pathway/ therapeutic targets, and epigenetics. Prof. Du has published more than 20 papers during the past decade in the first-class SCI journals, such as Cell Reports, Cancer Letters and others. He presided over several funds, including general projects of national Natural Science Foundation of China and special projects in key fields of biomedicine and health of Guangdong Provincial Department of Education. He has held several academic posts, including member of the first Tumor Whole-course Management Expert Committee of Guangdong Pharmaceutical Association, standing director of Intelligent and Digital Surgery Professional Committee of Shenzhen Medical Doctors Association, standing director of the second Council of Gastrointestinal Surgeons Branch of Shenzhen Medical Doctors Association, etc.

Personal Profile


Oncology; Surgery; Epigenetics; Molecular biology


Translational Medicine

For graduate students and undergraduate students higher than grade 3

Publications Read More


  1. Du C, Li SW, Singh SX, Roso K, Sun MA, Pirozzi CJ, Yang R, Li JL, He Y. Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization. Mol Cancer Res. 2021 Dec;19(12):2046-2056

  2. Han Z, Li M, Chen J, Ji D, Zhan T, Peng Y, Xue W, Li Y, Cai Y, Sun Y, Wu Q, Du C, Gu J. Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy. Asian J Surg. 2021 Apr 19; S1015-9584(21)00176-7
  3. Du C, Peng Y, He Y, Chen G, Chen H. Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer. Int J Biol Markers. 2021 Mar; 36(1):47-53.
  4. Dan C, Pei H, Zhang B, et al. Fanconi anemia pathway and its relationship with cancer[J]. Genome Instability & Disease, 2021: 1-9.
  5. Du C, Hansen LJ, Singh SX, Wang F, Sun R, Moure CJ, Roso K, Greer PK, Yan H, He Y. A PRMT5-RNF168-SMURF2 axis controls H2AX proteostasis. Cell rep. 2019, 28: 3199-3211.
  6. Du C, Huang D, Peng Y, Yao Y, Zhao Y, Yang Y, Wang H, Cao L, Zhu WG, Gu J. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. Cancer Lett. 2017 Aug 1; 400:183-193.
  7. Du C, Xue W, Dou F, Peng Y, Yao Y, Zhao J, Gu J. Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer. Int J Biol Markers. 2017 Jul 24; 32(3):e267-e273.
  8. Du C, Yao Y, Xue W, Zhu WG, Peng Y, Gu J. The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. BMJ Open. 2014; 4(8):e005012.
  9. Du C, Zhao J, Xue W, Dou F, Gu J. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy. Histopathology. 2013 Apr; 62(5):723-30.
  10. Du C, Xue W, Li J, Cai Y, Gu J. Morphology and prognostic value of tumor budding in rectal cancer after neoadjuvant radiotherapy. Hum Pathol. 2012 Jul; 43(7):1061-7.
  11. Du CZ, Chen YC, Cai Y, Xue WC, Gu J. Oncologic outcomes of primary and post-irradiated early stage rectal cancer: a retrospective cohort study. World J Gastroenterol. 2011 Jul 21; 17(27):3229-34.
  12. Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol. 2011 Apr 21; 17(15):2013-8.
  13. Du CZ, Xue WC, Cai Y, Li M, Gu J. Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: a retrospective cohort study. World J Gastroenterol. 2009 Aug 14; 15(30):3793-8.
  14. Du CZ, Gu J. Adoptability and limitation of cancer treatment guidelines: a Chinese oncologist’s perspective. Chin Med J (Engl). 2012 Mar; 125(5):725-7.
  15. Cao LL, Du C*, Liu H, Pei L, Qin L, Jia M, Wang H. Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. Int J Biol Markers. 2018 Apr 1:1724600818764069.(*co-first author)
  16. Hu D, Du C*, Xue W, Dou F, Yao Y, Gu J. The expression of chemokine receptors CCR6, CXCR2 and CXCR4 is not organ-specific for distant metastasis in colorectal cancer: a comparative study. Histopathology. 2013 Aug; 63(2):167-73. (*co-first author)
  17. Zhao J, Du CZ*, Sun YS, Gu J. Patterns and prognosis of locally recurrent rectal cancer following multidisciplinary treatment. World J Gastroenterol. 2012 Dec 21; 18(47):7015-20. (*co-first author)
  18. Huang D, Du C, Ji D, Xi J, Gu J. Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion. Tumour Biol. 2017 Jun; 39(6):1010428317705849.
  19. Li Z, Yang L, Du C, Fang X, Wang N, Gu J. Characteristics and comparison of colorectal cancer incidence in Beijing with other regions in the world. Oncotarget. 2017 Apr 11; 8(15):24593-24603.
  20. Tang M, Lu X, Zhang C, Du C, Cao L, Hou T, Li Z, Tu B, Cao Z, Li Y, Chen Y, Jiang L, Wang H, Wang L, Liu B, Xu X, Luo J, Wang J, Gu J, Wang H, Zhu WG. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. Theranostics. 2017; 7(5):1346-1359.
  21. Pan HD, Wang L, Peng YF, Li M, Yao YF, Zhao J, Zhan TC, Du CZ, Gu J. Subcutaneous vacuum drains reduce surgical site infection after primary closure of defunctioning ileostomy. Int J Colorectal Dis. 2015 Jul; 30(7):977-82.

    Zhang P, Ji DB, Han HB, Shi YF, Du CZ, Gu J. Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroenterol. 2014 Sep 14; 20(34):12241-8.

  22. Yao YF, Du CZ, Chen N, Chen P, Gu J. Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis. Dis Colon Rectum. 2014 May; 57(5):602-7.

    Zhan T, Gu J, Li M, Du C. Intermediate-fraction neoadjuvant radiotherapy for rectal cancer. Dis Colon Rectum. 2013 Apr; 56(4):422-32.

  23. Peng Y, Wang L, Du C, Gu J. Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy. Int J Colorectal Dis. 2012 Dec; 27(12):1555-60.
  24. Cai Y, Du C, Zhu X, Xu B, Gu J. Neoadjuvant therapy for advanced rectal carcinoma in China: Whether radiochemotherapy is superior to radiotherapy? Chin J Cancer Res. 2009 Jun; 21(4):295-262.
  25. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 2009 Sep; 55(3):284-93.

Lab members Read More

Join us

Contact Us

Contact Address

Office Phone


Copyright © 2018 All Rights Reserved.